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gattii Infection  
in Cat, Alaska, USA
To the Editor: We report a case 
of Cryptococcus gattii infection in 
a 12-year-old neutered male cat in 
Alaska. The cat traveled to Anchor-
age, Alaska (61°N) from San Diego 
County, California, with its owner in 
August 2003. Although C. gattii has 
not been detected in Alaska (where 
only extremely limited sampling has 
occurred) or above 49°N (i.e., Van-
couver Island, British Columbia), the 
case suggests that the incubation pe-
riod for C. gattii could be >8 years.
In September 2010, the cat was 
brought to a veterinary clinic in An-
chorage because of facial pruritis and 
excoriation. The cat did not respond 
to treatment with methylprednisolone 
acetate and was referred to a veteri-
nary dermatologist in October. At that 
time, alopecia, thick scaling, and ex-
coriations were observed on ear mar-
gins, sides of the head, and between 
the eyes. The hair coat was sparse, and 
there was minimal scaling near the 
tail and lower legs. All foot pads were 
excessively cross-hatched and scaly. 
Cytologic analysis of the skin on the 
head and pinna showed neutrophils and 
cocci overgrowth. Skin scrapings were 
negative for mites. Cytologic analysis 
of the ears did not identify yeast bod-
ies, parasites, or bacteria. A long-acting 
antimicrobial drug for treatment of skin 
infections (cefovecin) was given.
Biopsy specimens were obtained 
from the head, ears, and paws, and 
analysis of these samples supported 
a diagnosis of mural folliculitis and 
mild plasma cell pododermatitis. 
Chest radiograph findings and results 
of routine blood analysis were not un-
usual. Test results for feline leukemia 
virus and feline immunodeficiency vi-
rus were negative. Prednisolone (1.8 
mg/kg/d) was given; the cat showed a 
good response and eventual resolution 
of scaling. Hair grew back but the ste-
roid dose could not be reduced to <2.5 
mg/d because periodic increases were 
needed when symptoms flared.
In November 2011, the cat was 
brought back to the veterinary clinic 
because of worsening of the skin con-
dition even though the owner had in-
creased the prednisolone dose to 7.5 
mg/d during the previous 3 weeks. 
The cat had also started shaking its 
head frequently and had a unilateral 
right nasal discharge. Major nasal dis-
charge had not been a symptom pre-
viously reported by the owner. Cyto-
logic analysis of the discharge showed 
large yeast bodies consistent with a 
Cryptococcus sp. interspersed among 
neutrophils, cocci, and rods.
The cat was treated with flucon-
azole, and prednisolone was slowly 
decreased to minimal doses to control 
the mural folliculitis. After consulta-
tion with the Alaska Office of the State 
Veterinarian and Division of Public 
Health, a nasal swab specimen was 
sent to the Centers for Disease Con-
trol and Prevention (CDC) (Atlanta, 
GA, USA) for confirmation and mo-
lecular typing. Since 2009, Alaska has 
participated in the CDC-led Pacific 
Northwest C. gattii working group, 
which has been interested in enhanced 
surveillance for C. gattii (1,2). CDC 
identified the isolate as C. gattii mo-
lecular type VGIII; this type is com-
monly reported in the southern United 
States, particularly California (3).
Given what is known about the 
potential for dispersal of C. gattii (4), 
the owner was extensively interviewed 
about travel history of the cat and house-
hold members, and any travelers to or 
visitors from California who may have 
brought items into the house. The cat 
was rescued as a stray at ≈1 year of age 
in California, and after traveling to An-
chorage had lived as an indoor/outdoor 
cat without further travel. The family 
had not transported or received organic 
materials from California, except for 
an elongated (≈45 cm) seedpod. All 
plants and potting soil had been bought 
locally from national chain vendors. 
In May 2012, fifteen environmental 
samples, including soil from the yard, 
commercial potting soil, and a planter 
made from the seedpod brought from 
California, were taken from the home 
of the cat; all showed negative results 
for C. gattii when tested at CDC.
In humans, the average incuba-
tion period for C. gattii infection is 6 
weeks–13 months (5–7). Therefore, 
case-patients are usually asked to re-
call potential exposures during the 13 
months before symptom onset (5). Al-
though most reported cases of C. gattii 
infection appear to be primary infec-
tions, infrequent reports of C. gattii in-
fections in immunocompetent persons 
have described symptoms occurring 
several years after likely exposure, 
which suggests that C. gattii may have a 
greater capacity to remain dormant than 
believed (8–10). Incubation periods are 
not well described for animals but are 
generally reported as 2–11 months (R. 
Wohrle, pers. comm.). For either animal 
or human case-patients living in dis-
ease-endemic areas, precise incubation 
periods are likely incalculable because 
potential exposure to fungi is ongoing.
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We suspect that C. gattii infec-
tion in this cat resulted from a distant 
exposure in California. Although the 
cat left California >8 years ago, it re-
cently became immunosuppressed by 
medication that may have altered host 
factors, thus enabling latent fungi to 
clinically manifest. Results of limited 
environmental sampling in Alaska 
were negative. However, the molecu-
lar subtype supports California as a 
source, although the possibility that 
something or someone from Califor-
nia could have acted as a fomite could 
not be ruled out. Reactivation of a pre-
vious infection could also not be ruled 
out because the cat was a stray for the 
first year of its life.
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